Multimodal Postoperative Analgesia Following OSA Surgery

Multimodal Postoperative Analgesia Using Accufuser for Multilevel Surgery for Obstructive Sleep Apnea (OSA)

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04483427

Enrollment

Registered

2020-07-23

Start date

2020-09-20

Completion date

2022-12-31

Last updated

2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Brief summary

Assessment of the clinical efficacy and adverse effects of multimodal analgesic regimen consisting of nalbuphine combined with ketorolac using IV continuous infusion silicon device (Accufuser) for postoperative analgesia following multilevel OSA surgeries

Interventions

COMBINATION_PRODUCTNalbuphine, ketorolac, accufuser

multimodal analgesic regimen consisting of nalbuphine combined with ketorolac using IV continuous infusion silicon device (Accufuser)

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 50 Years

Healthy volunteers

Inclusion criteria

* physical status of American Society of Anesthesiologists (ASA) II * age between 30 - 50 years * OSA patients diagnosed by polysomnography and stop-bang questionnaire * enrolled for multilevel OSA surgery

Exclusion criteria

* history of allergy to the study drugs * history of hepatic, cardiopulmonary or renal disease * history of any chronic pain on medication * history of substance abuse * psychiatric disorder * lack of patient cooperation.

Design outcomes

Primary

Measure	Time frame	Description
Postoperative pain	Assessment will be carried out at zero time (time to shift to PACU) .	visual analog pain score

Secondary

Measure	Time frame	Description
Sedation level	Zero time ( time to shift to PACU)	Ramsey sedation scale
incidence of adverse effects	Zero time ( time to shift to PACU)	hypoxia, nausea, vomiting, itching

Countries

Egypt

Contacts

Primary ContactBahaa M Refaie, MD

bahaarefaay@med.sohag.edu.eg0201026887257

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026